Deflazacort Oral Suspension e Osteoporosi
Risultato del controllo d'interazione tra il farmaco Deflazacort Oral Suspension e la malattia Osteoporosi su sicurezza in caso d'uso simultaneo.
Durante il controllo d'interazione, secondo le fonti autorevoli Drugs.com, Rxlist.com, Webmd.com, Medscape.com sono trovate le controindicazioni o gli effetti collaterali che possono danneggiare oppure intensificare l’effetto negativo in caso d'uso del farmaco in presenza di questa malattia concomitante.
Consumatore:I corticosteroidi riducono funzione osteoblastica e inibire l'assorbimento intestinale di calcio, che può provocare il riassorbimento osseo e la perdita di massa ossea durante una terapia prolungata. Inoltre, la matrice ossea può essere influenzata dalle proteine effetti catabolici di corticosteroidi, soprattutto quando somministrato in dosi elevate o per periodi prolungati, che porta a necrosi asettica e fratture. A lungo termine o ad alte dosi di corticosteroidi terapia deve essere somministrata con cautela e solo se necessario, in pazienti con o a rischio di osteoporosi. Negativi scheletrico effetti possono essere minimizzati con l'alternativa di giorno o intermittente amministrazione. Ogni paziente che riceve una terapia prolungata con l'equivalente di 7,5 mg di prednisone al giorno o più sono a rischio indotta da glucocorticoidi osteoporosi e deve essere gestito secondo L'American College of Rheumatology (ACR) le linee guida.
- Goldstein MF, Fallon JJ, Harning R "Chronic glucocorticoid therapy-induced osteoporosis in patients with obstructive lung disease." Chest 116 (1999): 1733-49
- Anderton JM, Helm R "Multiple joint osteonecrosis following short-term steroid therapy. Case report." J Bone Joint Surg Am 64 (1982): 139-41
- Seale JP, Compton MR "Side-effects of corticosteroid agents." Med J Aust 144 (1986): 139-42
- "Product Information. Deltasone (prednisone)." Pharmacia and Upjohn, Kalamazoo, MI.
- "Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn, Kalamazoo, MI.
- Black KA, Khangure MS, Owen ET "Dexamethasone and osteonecrosis." Aust N Z J Med 11 (1981): 521-5
- Rizzato G, Montemurro L "Reversibility of exogenous corticosteroid-induced bone loss." Eur Respir J 6 (1993): 116-9
- "Product Information. Celestone (betamethasone)." Schering Corporation, Kenilworth, NJ.
- Fordyce MJ, Solomon L "Early detection of avascular necrosis of the femoral head by MRI." J Bone Joint Surg Br 75 (1993): 365-7
- Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. "Harrison's Principles of Internal Medicine. 14th ed." New York, NY: McGraw-Hill Health Professionals Division (1998):
- Archer AG, Nelson MC, Abbondanzo SL, Bogumill GP "Case report 554: Osteonecrosis at multiple sites as noted." Skeletal Radiol 18 (1989): 380-4
- Mitchison HC, Bassendine MF, Malcolm AJ, et al "A pilot, double-blind, controlled 1-year trial of prednisolone treatment in primary biliary cirrhosis: hepatic improvement but greater bone loss." Hepatology 10 (1989): 420-9
- Taylor LJ "Multifocal avascular necrosis after short-term high-dose steroid therapy. A report of three cases." J Bone Joint Surg Br 66 (1984): 431-3
- McCluskey J, Gutteridge DH "Avascular necrosis of bone after high doses of dexamethasone during neurosurgery." Br Med J (Clin Res Ed) 284 (1982): 333-4
- Fast A, Alon M, Weiss S, Zer-Aviv FR "Avascular necrosis of bone following short-term dexamethasone therapy for brain edema. Case report." J Neurosurg 61 (1984): 983-5
- Saisu T, Sakamoto K, Yamada K, Kashiwabara H, Yokoyama T, Iida S, Harada Y, Ikenoue S, Sakamoto M, Moriya H "High incidence of osteonecrosis of femoral head in patients receiving more than 2 g of intravenous methylprednisolone after renal transplantation." Transplant Proc 28 (1996): 1559-60
- "Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb, Princeton, NJ.
- Bijlsma JW, Duursma SA, Bosch R, Raymakers JA, Huber-Bruning O "Acute changes in calcium and bone metabolism during methylprednisolone pulse therapy in rheumatoid arthritis." Br J Rheumatol 27 (1988): 215-9
- Thomas TP "The complications of systemic corticosteroid therapy in the elderly." Gerontology 30 (1984): 60-5
- "Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb, Princeton, NJ.
- Elliott ME, Farrah RM, Binkley NC, Cames ML, Gudmundsson A "Management of glucocorticoid-induced osteoporosis in male veterans." Ann Pharmacother 34 (2000): 1380-4
- Marystone JF, Barrettconnor EL, Morton DJ "Inhaled and oral corticosteroids: their effects on bone mineral density in older adults." Am J Public Health 85 (1995): 1693-5
- Sambrook PN, Hassall JE, York JR "Osteonecrosis after high dosage, short term corticosteroid therapy." J Rheumatol 11 (1984): 514-6
- Cruess RL "Experience with steroid-induced avascular necrosis of the shoulder and etiologic considerations regarding osteonecrosis of the hip." Clin Orthop Jan-Feb(13 (1978): 86-93
- "Product Information. Decadron (dexamethasone)." Merck & Co, Inc, West Point, PA.
- Hahn TJ, Halstead LR, Baran DT "Effects of short term glucocorticoid administration on intestinal calcium absorption and circulating vitamin d metabolite concentrations in man." J Clin Endocrinol Metab 52 (1981): 111-5
- Packe GE, Douglas JG, McDonald AF, Robins SP, Reid DM "Bone density in asthmatic patients taking high dose inhaled beclomethasone diproprionate and intermittent systemic corticosteroids." Thorax 47 (1992): 414-7
- Ledford D, Apter A, Brenner AM, Rubin K, Prestwood K, Frieri M, Lukert B "Osteoporosis in the corticosteroid-treated patient with asthma." J Allergy Clin Immunol 102 (1998): 353-62
- Mizuta H, Kubota K, Shiraishi M, Kai K, Nakamura E, Takagi K "Steroid-related bilateral osteonecrosis of the patella." Arthroscopy 9 (1993): 114-6
- Weissman DE, Dufer D, Vogel V, Abeloff MD "Corticosteroid toxicity in neuro-oncology patients." J Neurooncol 5 (1987): 125-8
- "Product Information. Hydrocortone (hydrocortisone)." Merck & Co, Inc, West Point, PA.
- Need AG, Philcox JC, Hartley TF, Nordin BE "Calcium metabolism and osteoporosis in cortiscosteroid-treated postmenopausal women." Aust N Z J Med 16 (1986): 341-6
- "Product Information. Hydeltrasol (prednisolone)." Merck & Co, Inc, West Point, PA.
- Williams IA, Mitchell AD, Rothman W, Tallett P, Williams K, Pitt P "Survey of the long term incidence of osteonecrosis of the hip and adverse medical events in rheumatoid arthritis after high dose intravenous methylprednisolone." Ann Rheum Dis 47 (1988): 930-3
- Fentiman IS, Saad Z, Caleffi M, et al "Tamoxifen protects against steroid-induced bone loss." Eur J Cancer 28 (1992): 684-5
- "Product Information. Cortone Acetate (cortisone)." Merck & Co, Inc, West Point, PA.
Nome generico: deflazacort
Marchio commerciale: Emflaza
Sinonimo: Deflazacort